Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Event-driven TAF/FTC HIV PrEP in MSM (Thailand and France)
2022-502931-20-00Phase 3Authorised
- Sponsor
- Inserm
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Inserm. Planned start Mar 2023; status: authorised.
02
Drugs
emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-502931-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502931-20-00.